<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1481">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05141877</url>
  </required_header>
  <id_info>
    <org_study_id>KMUHIRB-F(II)-20210167</org_study_id>
    <nct_id>NCT05141877</nct_id>
  </id_info>
  <brief_title>Influences of Propofol and Sevoflurane Anesthesia in Brain Tumor</brief_title>
  <acronym>anesthetics</acronym>
  <official_title>Impact of Propofol-Based Total Intravenous Anesthesia Versus Anesthesia With Sevoflurane on Long-term Outcomes With Patients Undergoing Elective Craniotomy for Primary Brain Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaohsiung Medical University Chung-Ho Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaohsiung Medical University Chung-Ho Memorial Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the preoperative waiting area, the patients are randomly assigned and divided into two&#xD;
      groups according to the allocation sequence table (corresponding to 1:1 randomization)&#xD;
      generated by the computer. The propofol group was both induced and maintained at an&#xD;
      effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI)&#xD;
      system. The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3%&#xD;
      (target minimum alveolar concentration of 0.7-1.3). The following patient data were recorded,&#xD;
      the type of anesthesia, sex, age at the time of surgery, preoperative Karnofsky performance&#xD;
      status (KPS) score and functional capacity, the postoperative complications within 30 days&#xD;
      (according Clavien-Dindo classification), American Society of Anesthesiologists(ASA) physical&#xD;
      status scores, tumor size, intraoperative blood loss/transfusion, duration of surgery,&#xD;
      duration of anesthesia, total opioid (remifentanil/fentanyl/ propofol) use, postoperative&#xD;
      radiation therapy, postoperative chemotherapy, postoperative concurrent chemoradiotherapy,&#xD;
      the presence of disease progression, and 6-month, 1-year, and 3-year overall survival and&#xD;
      Karnofsky performance status score were recorded.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During the operation, the dose of anesthetic drugs (propofol/ fentanyl /remifentanil and&#xD;
      sevoflurane/ cisatracurium/ rocuronium) are adjusted to maintain the mean arterial pressure&#xD;
      and heartbeat fluctuations within 20% of the baseline value and Entropy (or BIS) value at&#xD;
      40-60in both groups. The following patient data were recorded, the type of anesthesia, sex,&#xD;
      age at the time of surgery, preoperative Karnofsky performance status (KPS) score and&#xD;
      functional capacity, the postoperative complications within 30 days (according Clavien-Dindo&#xD;
      classification), ASA physical status scores, tumor size, intraoperative blood&#xD;
      loss/transfusion, duration of surgery, duration of anesthesia, total opioid (remifentanil/&#xD;
      fentanyl/ propofol) use, postoperative radiation therapy, postoperative chemotherapy,&#xD;
      postoperative concurrent chemoradiotherapy, the presence of disease progression, and 6-month,&#xD;
      1-year, and 3-year overall survival and Karnofsky performance status score were recorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">November 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>6-month</time_frame>
    <description>6-month overall survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1-year</time_frame>
    <description>1-year overall survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3-year</time_frame>
    <description>3-year overall survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The presence of disease progression</measure>
    <time_frame>From the date of surgery until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months&quot;</time_frame>
    <description>cancer recurrence after the surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Karnofsky performance status score</measure>
    <time_frame>Baseline (before the day of surgery)</time_frame>
    <description>to access patients' functional impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications within 30 days</measure>
    <time_frame>The period from the day of surgery until postoperative 30 days</time_frame>
    <description>according to Clavien-Dindo classification</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">706</enrollment>
  <condition>Brain Tumor</condition>
  <arm_group>
    <arm_group_label>Propofol Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sevoflurane group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.</description>
    <arm_group_label>Propofol Group</arm_group_label>
    <other_name>propofol anesthesia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3).</description>
    <arm_group_label>Sevoflurane group</arm_group_label>
    <other_name>inhalation anesthesia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Twenty to eighty-year-old.&#xD;
&#xD;
          2. ASA class I-III.&#xD;
&#xD;
          3. Patients undergoing elective craniotomy for primary brain tumors under general&#xD;
             anesthesia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe mental disorder&#xD;
&#xD;
          2. Poor liver function&#xD;
&#xD;
          3. Pregnant or lactating women&#xD;
&#xD;
          4. Morbidly obese&#xD;
&#xD;
          5. Allergy to any of the drugs used in this study&#xD;
&#xD;
          6. Recurrent tumor or repeat surgery&#xD;
&#xD;
          7. Biopsy cases&#xD;
&#xD;
          8. Incomplete outcome-data&#xD;
&#xD;
          9. Palliative treatment after surgery&#xD;
&#xD;
         10. simultaneous treatment of other malignancies&#xD;
&#xD;
         11. Emergency surgery&#xD;
&#xD;
         12. Presence of other malignant tumors&#xD;
&#xD;
         13. Combined propofol and inhalation anesthesia or other anesthetics, such as ketamine or&#xD;
             dexmedetomidine&#xD;
&#xD;
         14. Diagnosed as benign brain tumor&#xD;
&#xD;
         15. cerebellum tumor and pituitary gland tumor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhi-Fu Wu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaohsiung Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhi-Fu Wu, MD</last_name>
    <phone>07-3121101</phone>
    <phone_ext>7035</phone_ext>
    <email>aneswu@gmail.com</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 18, 2021</study_first_submitted>
  <study_first_submitted_qc>December 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2021</study_first_posted>
  <last_update_submitted>December 1, 2021</last_update_submitted>
  <last_update_submitted_qc>December 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary brain tumor</keyword>
  <keyword>Propofol</keyword>
  <keyword>Sevoflurane</keyword>
  <keyword>Survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

